Calvary Health Care

calvarycare.org.au

Founded in 1885 by the Sisters of the Little Company of Mary, Calvary is a charitable, not-for-profit, Catholic health care organisation. Our mission is to provide quality, compassionate health care to the most vulnerable, including those reaching the end of their life. We're responsible for over 12,000 staff and volunteers, 15 Public and Private Hospitals, 15 Retirement and Aged Care Facilities and a national network of Community Care Centres.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CPD and Learning

POSTERA AND NEUROLUCENT PARTNERS ON IDENTIFYING SMALL-MOLECULE THERAPEUTICS FOR ALZHEIMER'S DISEASE

PostEra | November 27, 2020

news image

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...

Read More

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

news image

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More

INSURERS TAKE AIM AT BIG PHARMA. THIS SMALL-CAP STOCK STANDS TO WIN.

Fool.com | January 30, 2020

news image

The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as well. That's the stance the state of California has taken, anyway, with Governor Gavin Newsom announcing early this month the state is planning to launch its own prescription drug label. The Blue Cross B...

Read More

AMAZON INTENSIFIES PUSH INTO AUSTRALIAN PHARMACY WITH TRADEMARK APPLICATION

Smh | June 01, 2020

news image

Retail giant Amazon has intensified its push into Australia's highly competitive pharmaceuticals sector, brushing off industry opposition with a fresh trademark application for a range of private-label over-the-counter medications. Amazon filed the application for the 'BasicCare' trademark on Friday and refers to Amazon-branded medication which shoppers can buy directly from the e-commerce giant. The move comes as Amazon faces a fight with the Pharmacy Guild of Australia over a previ...

Read More
news image

CPD and Learning

POSTERA AND NEUROLUCENT PARTNERS ON IDENTIFYING SMALL-MOLECULE THERAPEUTICS FOR ALZHEIMER'S DISEASE

PostEra | November 27, 2020

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...

Read More
news image

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More
news image

INSURERS TAKE AIM AT BIG PHARMA. THIS SMALL-CAP STOCK STANDS TO WIN.

Fool.com | January 30, 2020

The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as well. That's the stance the state of California has taken, anyway, with Governor Gavin Newsom announcing early this month the state is planning to launch its own prescription drug label. The Blue Cross B...

Read More
news image

AMAZON INTENSIFIES PUSH INTO AUSTRALIAN PHARMACY WITH TRADEMARK APPLICATION

Smh | June 01, 2020

Retail giant Amazon has intensified its push into Australia's highly competitive pharmaceuticals sector, brushing off industry opposition with a fresh trademark application for a range of private-label over-the-counter medications. Amazon filed the application for the 'BasicCare' trademark on Friday and refers to Amazon-branded medication which shoppers can buy directly from the e-commerce giant. The move comes as Amazon faces a fight with the Pharmacy Guild of Australia over a previ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us